1. An image generating system comprising:
means adapted for acquiring document image data representative of a document;
a memory for storing the document image data;
means adapted to establish a page length corresponding to a number of pages associated with each document of a specific set of documents, wherein each document contains the same number of pages;
an inputting means adapted to store page data representative of a pre-set number of pages shared in common by each document of the specific set of documents; and
an image generating means adapted to generate, in the memory, image data of each document of the set of documents; and
means adapted for generating separator data so as to identify the image data into distinct portions based on stored page data.
2. The image generating system of claim 1 wherein the inputting means includes means adapted for manually inputting the pre-set page length including at least one of a keyboard, a user interface on the image generating device, and via a network application or web browser.
3. The image generating system of claim 1 further comprising means adapted to collect and stack the set of documents with the specified number of pages.
4. The image generating system of claim 1 further comprising means adapted for selecting the desired parameters for generating the image data.
5. The image generating system of claim 4 further comprising a display for generating an image of the document image data.
6. The image generating system of claim 1 wherein the image generating means includes optical character recognition systems, image generating devices, and other multif unction peripherals.
7. The image generating system of claim 1 wherein the image generating means generates the set of documents into TIFF files.
8. The image generating system of claim 1 further comprising:
means adapted to change the pre-set page length for each document to a new established page length; and
means adapted to generate separator data so as to identify the image data into distinct portions having the new pre-set page length.
9. A method for generating images comprising the steps of:
acquiring image data representative of a document;
storing the document image data in memory;
establishing a page length corresponding to a number of pages associated with each document of a specific set of documents, wherein each document contains the same number of pages;
inputting the page length for each document of the specific set of documents into an image generating apparatus as a pre-set value;
generating, in the memory, image data of each document of the set of documents; and
generating separator data so as to identify the image data into distinct portions based on the pre-set page length.
10. The method of claim 9 wherein the page length of the specific set of documents is manually input into the image generating apparatus via a keyboard, a user interface on the image generating device, and via a network application or web browser.
11. The method of claim 9 further comprising collecting and stacking the set of documents with the specified number of pages.
12. The method of claim 9 further comprising selecting the desired parameters for generating the image data.
13. The method of claim 12 further comprising a display for generating an image of the document image data.
14. The method of claim 9 wherein the image generating apparatus includes optical character recognition systems, image generating devices, and other multifunction peripherals.
15. The method of claim 9 wherein the image generating apparatus generates the set of documents into TIFF files.
16. The method of claim 9 further comprising:
changing the pre-set page length for each document to a new established page length; and
generating separator data as to identify the image data into distinct portions based on the new pre-set page length.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A vector comprising a nucleic acid sequence encoding a bonding partner, wherein the nucleic acid sequence encoding the bonding partner comprises a nucleic acid sequence encoding a carrier polypeptide and a nucleic acid sequence encoding a target sequence, wherein the nucleic acid sequence encoding the target sequence is heterologous to the nucleic acid sequence encoding the carrier polypeptide, and the target sequence comprises at least 2 cysteines and has the sequence of Cys-Cys-Rn, whether R is any amino acid and n is an integer from 1-100, and wherein when n\u22672, each R is selected independently from every other R in the sequence, but wherein the target sequence cannot be Cys-Cys-Xaa-Xaa-Cys-Cys (SEQ. ID NO: 1) wherein Xaa can be any amino acid, and wherein the target sequence reacts with a biarsenical molecule having the formula:
and tautomers, anhydrides, and salts thereof;
wherein:
each X1 or X2 is independently Cl, Br, I, ORa, or SRa, or
X1 and X2 together with the arsenic atom form a ring having the formula:
Ra is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
Z is 1,2-ethanediyl, 1,2-propanediyl, 2,3-butanediyl, 1,3-propanediyl, 1,2 benzenediyl, 4-methyl-1,2-benzenediyl, 1,2-cyclopentanediyl, 1,2-cyclohexanediyl, 3-hydroxy-1,2-propanediyl, 3-sulfo-1,2-propanediyl, or 1,2-bis(carboxy)-1,2-ethanediyl;
Y1 and Y2, are each independently H or CH3, or
Y1 and Y2 together form a ring such that the biarsenical molecule has the formula
wherein:
M is O, S, CH2, C(CH3)2, or NH;
R1 and R2 are each independently ORa, OAc, NRaRb, or H;
R3 and R4 are each independently H, F, Cl, Br, I, ORa, or Ra; or
R1 together with R3, or R2 together with R4, or both, form a ring in which
(i) one of R1 or R3 is C2-C3 alkyl and the other is NRa and
(ii) one of R2 and R4 is C2-C3 alkyl and the other is NRa;
Rb is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
Q is CRaRb, CRaORb, C\u2550O, or a spirolactone having the formula:
wherein the spiro linkage is formed at C1
2. The vector of claim 1, wherein the target sequence is Cys-Cys-X1-X1-X2-X1-X3-X1-X1-Cys-X1-Cys-X2 (SEQ. ID NO: 3), wherein:
X1 is an amino acid having a non-polar side chain,
X2 is an amino acid having a basic side chain, and
X3 is an amino acid having a non-ionic polar side chain.
3. The vector of claim 2, wherein X1 is glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, or tryptophan.
4. The vector of claim 2, wherein X2 is lysine, arginine, or histidine.
5. The vector of claim 2, wherein X3 is asparagine, glutamine, serine, or threonine.
6. The vector of claim 1, wherein the target sequence is Cys-Cys-gly-gly-lys-gly-asn-gly-gly-Cys-gly-Cys-his (SEQ. ID NO: 50).
7. The vector of claim 1, wherein the nucleic acid sequence encoding the target sequence is attached at the 5\u2032-end of the nucleic acid sequence encoding the carrier polypeptide.
8. The vector of claim 1, wherein the nucleic acid sequence encoding the target sequence is attached at the 3\u2032-end of the nucleic acid sequence encoding the carrier polypeptide.
9. The vector of claim 1, wherein the biarsenical molecule has the following structure:
10. A method of labeling a carrier molecule, comprising:
a) providing a bonding partner comprising the carrier molecule and a target sequence, and
b) contacting the bonding partner with a biarsenical molecule under conditions wherein the biarsenical molecule reacts with the target sequence, wherein the target sequence comprises at least 2 cysteines and has the sequence Cys-Cys-Rn, wherein R is any amino acid and n is an integer from 1-100, and wherein when n\u22672, each R is selected independently from every other R in the sequence, but wherein the target sequence cannot be Cys-Cys-Xaa-Xaa-Cys-Cys (SEQ. ID NO: 1) wherein Xaa can be any amino acid, and wherein the biarsenical molecule has the formula:
and tautomers, anhydrides, and salts thereof;
wherein:
each X1 or X2 is independently Cl, Br, I, ORa, or SRa, or
X1 and X2 together with the arsenic atom form a ring having the formula:
Ra is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
Z is 1,2-ethanediyl, 1,2-propanediyl, 2,3-butanediyl, 1,3-propanediyl, 1,2 benzenediyl, 4-methyl-1,2-benzenediyl, 1,2-cyclopentanediyl, 1,2-cyclohexanediyl, 3-hydroxy-1,2-propanediyl, 3-sulfo-1,2-propanediyl, or 1,2-bis(carboxy)-1,2-ethanediyl;
Y1 and Y2 are each independently H or CH3, or
Y1 and Y2 together form a ring such that the biarsenical molecule has the formula
wherein:
M is O, S, CH2, C(CH3)2, or NH;
R1 and R2 are each independently ORa, OAc, NRaRb, or H;
R3 and R4 are each independently H, F, Cl, Br, I, ORa, or Ra; or
R1 together with R3, or R2 together with R4, or both, form a ring in which
(i) one of R1 or R3 is C2-C3 alkyl and the other is NRa and
(ii) one of R2 and R4 is C2-C3 alkyl and the other is NRa;
Rb is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
Q is CRaRb, CRaORb, C\u2550O, or a spirolactone having the formula:
wherein the spiro linkage is formed at C1.
11. The method of claim 10, wherein the biarsenical molecule generates a detectable signal.
12. The method of claim 11, further comprising monitoring the detectable signal.
13. The method of claim 11, wherein the signal is a fluorescent signal.
14. The method of claim 10, wherein the biarsenical molecule is coupled to a solid phase.
15. The method of claim 10, wherein the target sequence is coupled to a solid phase.
16. The method of claim 10, wherein the carrier molecule is a polypeptide.
17. The method of claim 16, wherein the polypeptide is an antibody or an enzyme.
18. The method of claim 10, wherein the target sequence is Cys-Cys-X1-X1-X2-X1-X3-X1-X1-Cys-X1-Cys-X2 (SEQ. ID NO: 3), wherein:
X1 is an amino acid having a non-polar side chain,
X2 is an amino acid having a basic side chain, and
X3 is an amino acid having a non-ionic polar side chain.
19. The method of claim 18, wherein X1 is glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, or tryptophan.
20. The method of claim 18, wherein X2 is lysine, arginine, or histidine.
21. The method of claim 18, wherein X3 is asparagine, glutamine, serine, or threonine.
22. The method of claim 10, wherein the target sequence is Cys-Cys-gly-gly-lys-gly-asn-gly-gly-Cys-gly-Cys-his (SEQ. ID NO: 50).
23. A kit comprising:
a) a biarsenical molecule having the structure:
and tautomers, anhydrides, and salts thereof;
wherein:
each X1 or X2 is independently Cl, Br, I, ORa, or SRa, or
X1 and X2 together with the arsenic atom form a ring having the formula:
Ra is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
Z is 1,2-ethanediyl, 1,2-propanediyl, 2,3-butanediyl, 1,3-propanediyl, 1,2 benzenediyl, 4-methyl-1,2-benzenediyl, 1,2-cyclopentanediyl, 1,2-cyclohexanediyl, 3-hydroxy-1,2-propanediyl, 3-sulfo-1,2-propanediyl, or 1,2-bis(carboxy)-1,2-ethanediyl;
Y1 and Y2 are each independently H or CH3, or
Y1 and Y2 together form a ring such that the biarsenical molecule has the formula
wherein:
M is O, S, CH2, C(CH3)2, or NH;
R1 and R2 are each independently ORa, OAc, NRaRb, or H;
R3 and R4 are each independently H, F, Cl, Br, I, ORa, or Ra; or
R1 together with R3, or R2 together with R4, or both, form a ring in which
(i) one of R1 or R3 is C2-C3 alkyl and the other is NRa and
(ii) one of R2 and R4 is C2-C3 alkyl and the other is NRa;
Rb is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
Q is CRaRb, CRaORb, C\u2550O, or a spirolactone having the formula:
wherein the spiro linkage is formed at C1; and
b) a bonding partner comprising a target sequence, wherein the target sequence comprises at least 2 cysteines and has the sequence Cys-Cys-Rn, wherein R is any amino acid and n is an integer from 1-100, and wherein when n\u22672, each R is selected independently from every other R in the sequence, but wherein the target sequence cannot be Cys-Cys-Xaa-Xaa-Cys-Cys (SEQ. ID NO: 1) wherein Xaa can be any amino acid, and wherein the target sequence reacts with the biarsenical molecule.
24. The kit of claim 23, wherein the target sequence is Cys-Cys-X1-X1-X2-X1-X3-X1-X1-Cys-X1-Cys-X2 (SEQ. ID NO: 3), wherein:
X1 is an amino acid having a non-polar side chain,
X2 is an amino acid having a basic side chain, and
X3 is an amino acid having a non-ionic polar side chain.
25. The kit of claim 24, wherein X1 is glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, or tryptophan.
26. The kit of claim 24, wherein X2 is lysine, arginine, or histidine.
27. The kit of claim 24, wherein X3 is asparagine, glutamine, serine, or threonine.
28. The kit of claim 23, wherein the target sequence is Cys-Cys-gly-gly-lys-gly-asn-gly-gly-Cys-gly-Cys-his (SEQ. ID NO: 50).
29. A method of purifying a bonding partner, comprising:
a) providing a bonding partner comprising a target sequence, comprises at least 2 cysteines and has the sequence of Cys-Cys-Rn, whether R is any amino acid and n is an integer from 1-100, and wherein when n\u22672, each R is selected independently from every other R in the sequence, but wherein the target sequence cannot be Cys-Cys-Xaa-Xaa-Cys-Cys (SEQ. ID NO: 1) wherein Xaa can be any amino acid, and wherein the target sequence reacts with a biarsenical molecule having the structure:
and tautomers, anhydrides, and salts thereof;
wherein:
each X1 or X2 is independently Cl, Br, I, ORa, or SRa, or
X1 and X2 together with the arsenic atom form a ring having the formula:
Ra is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
Z is 1,2-ethanediyl, 1,2-propanediyl, 2,3-butanediyl, 1,3-propanediyl, 1,2 benzenediyl, 4-methyl-1,2-benzenediyl, 1,2-cyclopentanediyl, 1,2-cyclohexanediyl, 3-hydroxy-1,2-propanediyl, 3-sulfo-1,2-propanediyl, or 1,2-bis(carboxy)-1,2-ethanediyl;
Y1 and Y2 are each independently H or CH3, or
Y1 and Y2 together form a ring such that the biarsenical molecule has the formula
wherein:
M is O, S, CH2, C(CH3)2, or NH;
R1 and R2 are each independently ORa, OAc, NRaRb, or H;
R3 and R4 are each independently H, F, Cl, Br, I, ORa, or Ra; or
R1 together with R3, or R2 together with R4, or both, form a ring in which
(i) one of R1 or R3 is C2-C3 alkyl and the other is NRa and
(ii) one of R2 and R4 is C2-C3 alkyl and the other is NRa;
Rb is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
Q is CRaRb, CRaORb, C\u2550O, or a spirolactone having the formula:
wherein the spiro linkage is formed at C1;
d) contacting the bonding partner with the biarsenical molecule, wherein the biarsenical molecule is coupled to a solid phase,
e) eluting the bonding partner from the biarsenical molecule by contacting the biarsenical molecule with a dithiol.
30. The method of claim 29, wherein the carrier molecule is a protein.
31. The method of claim 30, wherein the protein is an antibody or an enzyme.
32. The method of claim 29, wherein the biarsenical compound is membrane permeable.
33. The method of claim 29, wherein the dithiol is selected from the group consisting of 1,2-benzendithiol, 1,2-cyclohexanedithiol and 1,2-ethanedithiol.
34. An isolated polypeptide comprising a sequence Cys-Cys-X1-X1-X2-X1-X3-X1-X1-Cys-X1-Cys-X2 (SEQ. ID NO: 3), wherein:
X1 is an amino acid having a non-polar side chain,
X2 is an amino acid having a basic side chain, and
X3 is an amino acid having a non-ionic polar side chain.
35. The polypeptide of claim 34, wherein X1 is glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, or tryptophan.
36. The polypeptide of claim 34, wherein X2 is lysine, arginine, or histidine.
37. The polypeptide of claim 34, wherein X3 is asparagine, glutamine, serine, or threonine.
38. An isolated polypeptide comprising a sequence Cys-Cys-Gly-Gly-Lys-Gly-Asn-Gly-Gly-Cys-Gly-Cys-His (SEQ. ID. NO: 50).
39. An isolated nucleic acid molecule encoding a polypeptide having a sequence Cys-Cys-X1-X1-X2-X1-X3-X1-X1-Cys-X1-Cys-X2 (SEQ. ID NO: 3), wherein:
X1 is an amino acid having a non-polar side chain,
X2 is an amino acid having a basic side chain, and
X3 is an amino acid having a non-ionic polar side chain.
40. The isolated nucleic acid molecule of claim 39, wherein X1 is glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, or tryptophan.
41. The isolated nucleic acid molecule of claim 39, wherein X2 is lysine, arginine, or histidine.
42. The isolated nucleic acid molecule of claim 39, wherein X3 is asparagine, glutamine, serine, or threonine.
43. An isolated nucleic acid molecule encoding a polypeptide having a sequence Cys-Cys-Gly-Gly-Lys-Gly-Asn-Gly-Gly-Cys-Gly-Cys-His (SEQ. ID. NO: 50).